![](/img/cover-not-exists.png)
Corrigendum to ‘‘An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension” [Regul. Toxicol. Pharmacol. 2012, 95–103]
Owen, Keith, Cross, David M., Derzi, Mazin, Horsley, Elizabeth, Stavros, Fiona L.Volume:
64
Language:
english
Journal:
Regulatory Toxicology and Pharmacology
DOI:
10.1016/j.yrtph.2012.07.012
Date:
December, 2012
File:
PDF, 120 KB
english, 2012